Enterome
ID: 5635856
Seedtable Score
48
Startups
7
Funding Rounds
4
Investors
$127.76m
Money raised
Recent Funding Rounds
Overview
Enterome's focus on immunomodulatory drugs positions it well in the health and biopharma sectors, particularly in cancer and immune diseases. Based in Paris and operating on a B2B model, the company leverages research in immune system modulation to develop treatments that may complement existing therapies like chemotherapy and immunotherapies. Its specialized approach offers a competitive edge, potentially leading to more effective treatments, faster recovery times, and improved survival rates. Backed by investors such as The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Nestlé Health Science, Enterome shows strong market confidence and strategic support, enhancing its growth prospects in the biotech landscape.
- Website: https://enterome.com
- Business model: b2b
- Company size: 51 - 101 employees
- Headquarters: Paris, France
- Founded: 2012
- Social accounts: Twitter Linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Investors (4)
Funding
Funding series
Funding Series Analysis
The company Enterome has raised a total of $127.76m in funding over 7 rounds.
Key Insights:
- Series E: $52.09m
- Series D: $34.8m
- Series C: $15.9m
- Series B: $12m
- Series A: $8.2m
- Seed: $1.6m
- Series F: $3.17m
Enterome Seed (2011, $1M)
$1.6m
Enterome Series B (2014, $12M)
$12m
Enterome Series D (2017, $34M)
$34.8m
Enterome Series E (2020, $52M)
$52.09m
Enterome Series C (2016, $15M)
$15.9m
Enterome Series A (2012, $8M)
$8.2m
Enterome Series F (2023, $3M)
$3.17m